Vertaling van "cans containing " (Nederlands → Frans) :

TERMINOLOGIE

container voor bloedverwerkend autotransfusiesysteem
conteneur pour système d’autotransfusion et traitement de sang

container voor bloed- of weefselopslag of -kweek
conteneur de stockage/culture de sang/tissus

container voor cytotoxisch afval
réceptacle à déchets cytotoxiques

container voor besmet afval
réceptacle à déchets contaminés

IN-CONTEXT TRANSLATIONS

Mupirocin susceptibility can adequately be tested with the Kirby Bauer disc diffusion method using a paper disc/tablet containing 5 or 10 µg of mupirocin (Oxoid/Rosco) to detect low-level resistance, and / or a 200 µg disc (Oxoid) for high-level resistance.
La sensibilité à la mupirocine peut être examinée de manière adéquate avec la méthode de diffusion en gélose utilisant des disques de Kirby Bauer en se servant d’un disque de papier contenant 5 ou 10 µg de mupirocine (Oxoid/Rosco) pour détecter la résistance de faible niveau, et/ou un disque de 200 µg (Oxoid) pour la résistance à niveau élevé.

One can either use selective enrichment (containing salt and/or antibiotics) and subsequently nonselective solid media, or non-selective enrichment followed by inoculation on selective solid media (e.g. mannitol salt agar supplemented with 4 to 6 mg/L of oxacillin).
On peut employer soit un enrichissement sélectif (contenant du sel et/ou des antibiotiques) suivi de milieux solides non sélectifs, soit un enrichissement non sélectif suivi d'une inoculation sur des milieux solides sélectifs (par exemple de la gélose au sel de mannitol additionné de 4 à 6 mg/l d'oxacilline).

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

After investigating the existing preparations, the experts first focussed on caffeine and concluded that a daily intake of 160 mg caffeine/day – in the form of cans containing up to 320 mg/litre - amounts to a considerable contribution to the total daily caffeine intake.
Après analyse des préparations existantes, les experts se sont tout d’abord penchés sur la caféine et ont conclu qu’un apport de 160 mg de caféine/jour par l’intermédiaire de cannettes contenant un niveau maximal de 320 mg/litre représente une contribution significative à l’apport journalier total en caféine.

Each 250 ml bottle of this product contains the following ingredients (the following list is restricted to the ingredients that can cause problems in terms of food safety): 80 mg caffeine (or 320 mg/litre), 1 000 mg taurine (4 000 mg/litre), 600 mg glucuronolactone (2 400 mg/litre), 5 µg vitamin B12, 5 µg vitamin B6, 5 mg vitamin B5, 1.5 mg vitamin B2 and 20.5 mg vitamin B3.
Celle-ci contient, par flacon de 250 ml, les composants suivants (liste limitée aux substances pouvant poser problème en termes de sécurité alimentaire): 80 mg de caféine (soit 320 mg/litre), 1.000 mg de taurine (4.000 mg/litre), 600 mg de D-glucuronolactone (2.400 mg/litre), 5 µg de vitamine B12, 5 mg de vitamine B6, 5 mg de vitamine B5, 1,5 mg de vitamine B2 et 20,5 mg de vitamine B3.